Flower offers sterile-packaged anatomic foot/ankle implants, allografts and diabetic wound care solutions for orthopedic surgeons and podiatrists.
Conventus is known for its platform proprietary nitinol expandable CAGE™ technology to treat proximal humerus and distal radius fractures with reportedly greater stability and fewer complications vs. plating. Lower extremity CAGE implants are in development.
The move follows Conventus’ 4Q19 acquisition of an intramedullary distal fibula system from Surgical Frontiers. Conventus seeks to expand its distribution channel and enhance its portfolio through product development and acquisitions. Specifically, the company intends to pursue technologies that are clinically relevant to hospitals, ambulatory surgery centers and surgeons.
Dr. Roy Sanders, Chief, Orthopaedic Surgery, Tampa General Hospital commented that, “As more and more foot and ankle procedures migrate to short stay ASCs, and as 23-hour facilities increase across the country, [Flower’s] sterile packaged, anatomic implants will continue to offer attractive quality and value to surgeons everywhere. Combined with their wound and diabetic products, they are a natural fit with other products in the Conventus pipeline, which recognizes the increasing shift to outpatient surgery throughout the U.S.”
Flower offers sterile-packaged anatomic foot/ankle implants, allografts and diabetic wound care solutions for orthopedic surgeons and podiatrists.
Conventus is known for its platform proprietary nitinol expandable CAGE™ technology to treat proximal humerus and distal radius fractures with reportedly greater stability and fewer complications vs. plating. Lower extremity CAGE implants are in development.
The move follows Conventus’ 4Q19 acquisition of an intramedullary distal fibula system from Surgical Frontiers. Conventus seeks to expand its distribution channel and enhance its portfolio through product development and acquisitions. Specifically, the company intends to pursue technologies that are clinically relevant to hospitals, ambulatory surgery centers and surgeons.
Dr. Roy Sanders, Chief, Orthopaedic Surgery, Tampa General Hospital commented that, “As more and more foot and ankle procedures migrate to short stay ASCs, and as 23-hour facilities increase across the country, [Flower’s] sterile packaged, anatomic implants will continue to offer attractive quality and value to surgeons everywhere. Combined with their wound and diabetic products, they are a natural fit with other products in the Conventus pipeline, which recognizes the increasing shift to outpatient surgery throughout the U.S.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
